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Purpose of the study
LPV/r-based HAART is a common treatment regimen for
HIV-1 disease. We conducted a large observational study
of patients currently taking LPV/r-based therapy (LPV/r T)
in an attempt to describe patient satisfaction or lack
thereof with LPV/r T. We concurrently conducted a physi-
cian survey to describe physician impressions of their
patients' satisfaction.
Methods
Patients self-administered three questionnaires (qst.) at
one visit: modified HIVTSQ treatment satisfaction qst.1;
EuroQoL quality of life (QoL) qst.2; and the 5-item qst.
further probing QoL, adherence, daily activity, tolerability
and satisfaction with treatment. Physicians independently
completed the 5-item qst. It was a multicenter cross-sec-
tional observational study throughout Spain (participants
size/center limited to reduce regional/center bias).
Patients were required to be taking a LPV/r (tablets) based
therapy for >1 month. Dataset analysed as a whole, and
both by naïve- vs. ARV-experienced, and by duration of
LPV/r T (Cohort CH1: 1–3 months; CH2: >3 months <2
years and CH3: >2 years).
Summary of results
1,109 patients and 97 doctors participated. Patient mean
age 42.6 years; 27.4% female, and 31.5% were naïve prior
to LPV/r T. Patients by duration of exposure ; CH1: 315,
CH2: 394, CH3: 400. Mean HIVTSQ scores (over 100) per
dimension were: general/clinical satisfaction, 83.0 ± 15.4;
lifestyle, 75.2 ± 16.5; and overall satisfaction, 79.5 ± 14.0.
Mean EuroQoL score (over 10) was 7.40 ± 1.64. For the 5-
item qst. patient reporting was, 90.9% no-very little
impact on QoL, 80.7% considered LPV/r T well-very well
tolerated, 89.4% were well-very well compliant, 88.8%
had no-very few difficulties on daily activities, and 82.7%
high-very high satisfaction on LPV/r T. Corresponding
physicians' answers were 86.7%, 85.4%, 87.0%, 88.9%
and 79.0%, respectively (high concordance with patient's
findings in reporting of satisfaction was shown). Findings
from the HIVTSQ did not show significant satisfaction dif-
ferences between previously ARV-naïve vs. -experienced
patients. Total satisfaction scores were greater with time
on LPV/r T (CH3>2>1, p < 0.001).
Conclusion
Overall, reported patient satisfaction level with LPV/r T
was high. Not surprisingly, patients with the longest expo-
sure duration reported the highest levels of satisfaction.
Additional patient satisfaction studies conducted among
patients on differing anchor antiretrovirals would provide
further context, comparison, and interpretation for these
LPV/r treatment satisfaction findings.
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